Company Profile
4D Molecular Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- FDMT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
10.55 USD (+2.63%)
Close
Last updated: August 6, 2026
485M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, FDMT closed up 2.63% at $10.55. No new same-company headline was identified in the current news window.
Company overview
Business overview
4D Molecular Therapeutics is a gene-therapy company focused on precision engineered viral vectors and genetic medicine. Its story centers on using vector engineering to improve tissue targeting and therapeutic performance.
Geographic Base and Sector Classification
4DMT is headquartered in the United States and listed on NASDAQ. It sits in gene therapy and platform biotechnology.
Business Model Characteristics
The company depends on platform validation, clinical progress, and the ability to convert vector engineering into clinically meaningful products. Investors follow data, safety, and strategic development milestones.
Position Within the Biotechnology Landscape
4D Molecular Therapeutics occupies a premium gene-therapy platform niche within biotech. The stock is catalyst-sensitive because the market is still proving how powerful its vector-engineering approach can be.
Future catalysts
4D Molecular Therapeutics's catalysts are 4D-150 and 4D-310, the gene-therapy programs the market will use to judge whether the platform is still gaining traction. Each data update matters because the story is still mostly about platform validation.
Recent news
- 01
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Source: 4D Molecular Therapeutics, Inc.
- 02
4DMT Announces New Employment Inducement Grants
Source: 4D Molecular Therapeutics, Inc.
- 03
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
Source: 4D Molecular Therapeutics, Inc.
- 04
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
Source: 4D Molecular Therapeutics, Inc.
- 05
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
Source: 4D Molecular Therapeutics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of 4D Molecular Therapeutics, Inc. (FDMT)?
4D Molecular Therapeutics, Inc. (FDMT) most recently closed at 10.55 USD, a +2.63% move versus the previous session.
What is the market cap of 4D Molecular Therapeutics, Inc. (FDMT)?
4D Molecular Therapeutics, Inc. currently has a market capitalization of 485M USD on BioPharmSignal.
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics is a gene-therapy company focused on precision engineered viral vectors and genetic medicine. Its story centers on using vector engineering to improve tissue targeting and therapeutic performance.
On which exchange is FDMT stock listed?
4D Molecular Therapeutics, Inc. (FDMT) is associated with NASDAQ, United States, Biopharma.
What is Molecular?
4D Molecular Therapeutics's catalysts are 4D-150 and 4D-310, the gene-therapy programs the market will use to judge whether the platform is still gaining traction.
Which conditions is 4D Molecular Therapeutics, Inc. targeting with Molecular?
4D Molecular Therapeutics, Inc. is associated with genetic disease based on its company overview and current catalyst commentary.
How does 4D Molecular Therapeutics, Inc. describe recent progress with Molecular?
4D Molecular Therapeutics's catalysts are 4D-150 and 4D-310, the gene-therapy programs the market will use to judge whether the platform is still gaining traction.
What is Therapeutics?
4D Molecular Therapeutics is a gene-therapy company focused on precision engineered viral vectors and genetic medicine.